Cytori Therapeutics, Inc. (CYTX) Technology Selected For NHLBI Funded Trial In LVAD Patients
7/22/2014 3:59:47 PM
SAN DIEGO--(BUSINESS WIRE)--The Cardiovascular Cell Therapy Research Network (CCTRN), has selected Cytori (NASDAQ: CYTX) Therapeutics, Inc. to supply adipose-derived regenerative cells (ADRCs™) for a clinical trial aimed at evaluating the safety and feasibility of treating patients with Left Ventricular Assist Devices (LVADs). The CCTRN is supported by grants from the National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH). This trial, named CELLVAD-ADRC, will explore outcomes following administration of a regenerative cell preparation from adipose tissue into the patient’s heart muscle 60 to 90 days after placement of an LVAD.
Help employers find you! Check out all the jobs and post your resume.
comments powered by